3Vote!
Forex Analytics (Free subscription) | 22/11/2009
Pharmaceutical company AstraZeneca plc (AZN, AZN.L) said Thursday it has submitted has New Drug Application for ticagrelor to the U.S. Food and Drug Administration. Ticagrelor is oral year investigational antiplatelet treatment to reduce unfavourable major cardiac vents in patients with acute coronary syndrome. The proposed trade name for ticagrelor is Brilinta, which is yet to [...] Post from: (c)Autor:...
3Vote!
PharmaGossip (Free subscription) | 21/11/2009
Companies: Astrazeneca Plc BOSTON, Nov. 20 /PRNewswire/ -- The United States Court of Appeals for the First Circuit upheld an earlier District Court ruling yesterday, approving a settlement in the long-running Average Wholesale Price (AWP) pharmaceutical litigation against AstraZeneca Pharmaceuticals (NYSE: AZN - News ). (Logo: http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO ) The ruling affirms...
3Vote!
The Legal Reader (Free subscription) | 20/11/2009
If so, I foresee a lot of money being spent by both sides to retain local counsel… Nov. 19 (Bloomberg) -- AstraZeneca Plc may face as many 6,000 trials of lawsuits claiming its antipsychotic drug Seroquel causes diabetes after a...
3Vote!
PharmaGossip (Free subscription) | 19/11/2009
Nov. 19 (Bloomberg) -- AstraZeneca Plc may face as many 6,000 trials of lawsuits claiming its antipsychotic drug Seroquel causes diabetes after a judge said she will recommend sending the cases back to their home courts. U.S. District Judge Anne Conway in Orlando, Florida, who is overseeing pre-trial proceedings in federal Seroquel litigation, said yesterday she’ll urge a panel of judges to...
3Vote!
Canadian Online Health News (Free subscription) | 19/11/2009
LONDON - AstraZeneca PLC said Thursday it has applied to U.S. regulators to market its blood clot preventer Brilinta, a potential new big seller for the company. AstraZeneca submitted a new drug application to the U.S.
3Vote!
Market Watch (Free subscription) | 17/11/2009
BOSTON (MarketWatch) -- The Food and Drug Administration warned Tuesday that taking the blood-thinner Plavix with the antacid Prilosec can reduce Plavix's effectiveness by as much as half. Plavix, the world's second best-selling drug, is co-marketed by Sanofi-Aventis and Bristol-Myers Squibb . Prilosec, also known as omeprazole, belongs to a group of widely-used antacids called PPIs. The agency also...
3Vote!
Sify (Free subscription) | 13/11/2009
Eli Lilly&Co. said Friday its science and technology head will retire. The drugmaker hired the chief researcher at AstraZeneca PLC to replace him.
3Vote!
Sify (Free subscription) | 13/11/2009
Eli Lilly&Co. said Friday its science and technology head will retire and that it has hired the chief researcher at AstraZeneca PLC to replace him.
3Vote!
Miami Herald (Free subscription) | 13/11/2009
Eli Lilly & Co. said Friday its science and technology head will retire and that it has hired the chief researcher at AstraZeneca PLC to replace him.
3Vote!
Miami Herald (Free subscription) | 13/11/2009
Eli Lilly & Co. said Friday its science and technology head will retire and that it has hired the chief researcher at AstraZeneca PLC to replace him.
3Vote!
Seattle Times (Free subscription) | 13/11/2009
Eli Lilly & Co. said Friday its science and technology head will retire and that it has hired the chief researcher at AstraZeneca PLC to replace him.
3Vote!
Philadelphia Inquirer (Free subscription) | 30/10/2009
Drugmaker AstraZeneca P.L.C. said yesterday that it had set aside $520 million as part of a tentative agreement to resolve an investigation by federal prosecutors in Philadelphia into the company's marketing practices.
3Vote!
Examiner (Free subscription) | 29/10/2009
Pharmaceutical company AstraZeneca PLC posted a 22 percent rise in third quarter net profit on Thursday, boosted by initial sales of its swine flu vaccine and delayed entry of generic drug competition in the United States.
3Vote!
kansascity.com (Free subscription) | 29/10/2009
Pharmaceutical company AstraZeneca PLC has reported an 22 percent rise in third quarter net profit, boosted by initial sales of its swine flu vaccine and delayed entry of generic drug competition in the United States.
3Vote!
Seattle Times (Free subscription) | 29/10/2009
Pharmaceutical company AstraZeneca PLC has reported an 22 percent rise in third quarter net profit, boosted by initial sales of its swine flu vaccine and delayed entry of generic drug competition in the United States.
Videos